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 1 
CHAPTER 1: INTRODUCTION AND LITERATURE REVIEW 
 
Severe mental illness (SMI) is responsible for 7.4% of the global disease burden (1) and is estimated 
to account for 6% of the disease burden in South Africa (2). Schizophrenia is a disorder with positive 
symptoms (disturbance in perception, belief or thinking and disorganized behavior), negative symp-
toms (weak social interaction, poverty of speech and or anhedonia), mood symptoms and cognitive 
deficits (3). Evidence shows schizophrenia to have the highest disability burden compared to other 
diseases in this category of SMI (4). Almost half of those diagnosed with schizophrenia meets the 
criteria for a specific substance use disorder (SUD) (5). The term dual diagnosis is clinically used 
to categorize individuals diagnosed with mental illness and a co-occurring substance use disorder. 
The occurrence or presence of a dual diagnosis compounds the existing disability burden, affects 
the overall outcome, predicts poor prognosis, and has treatment implications (6-9). The cost of fail-
ing to address mental health is higher than the cost of treating mental illness by a range of two to 
six times more (6). Low and middle-income country (LMIC) such as South Africa, cannot sustain-
ably afford the estimated financial cost attached to poor treatment outcomes and existing treatment 
gap (2). 
 
Global mental health efforts in reducing the burden associated with schizophrenia call for clinical 
practices that improve quality of life by prioritizing functional recovery (10). The mainstay man-
agement of schizophrenia is antipsychotic treatment with adjunct individualized psychosocial inter-
ventions (11, 12). Despite available effective treatments options, more than 75% of those living with 
SMI in LMICs do not receive the care they need. Hence a greater than half of those receiving treat-
ment, fail to comply with their prescribed treatment and relapse (13, 14). Poor adherence to pre-
scribed antipsychotic treatment remains a key obstacle in achieving the targeted functional recovery 
among individuals with schizophrenia (10). Desired outcomes could be attained by incorporating 
early treatment and interventions that target poor treatment adherence(15, 16). 
  
Poor treatment adherence can be predicted by an individual's subjective wellbeing while on neuro-
leptic treatment (SWBN) (17).SWBN is also a good predictor early response and prognosis in pa-
tients with schizophrenia (17-19). The term “subjective well-being” has been defined as an individ-
ual’s perceived mental, physical and emotional assessment of themselves(20) and among the con-
structs used to asses a patient’s quality of life (21). Factors that influence subjective well-being and 
consequently, the quality of life include those related to the i) patient, ii) treatment or iii) the illness 
(22). Interventions that target these factors at an individual and community level provide for an 
opportunity to address challenges in the management of SMI, improve outcomes, and subsequently 
reduce direct and indirect costs of SMI. Predictors of subjective well-being are extensively re-
searched, but the availability of data limited to studies conducted in high-income countries (HICs). 
Little is known about factors that are specific to patients living in LMICs and particularly in an 
African setting (23-26). This chapter reviews evidence for specific scale to quantify SWBN, sum-
marises available literature on the predictors of SWBN, and concludes with proposed research ques-
tions aimed at addressing identified knowledge gaps. 
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METHODOLOGY OF THE LITERATURE REVIEW 
The literature search was performed using PsychInfo via EBSCOhost. The search was restricted to 
research and reviews published in scientific journals between January 2006 and March 2016 with 
an adult (greater than 18 years of age) population sample. The search terms used were "Schizophre-
nia "and" "subjective well-being." A total of 25 publications were identified. A narrative review was 
conducted. A paucity of data and literature from LMICs has been observed. A comprehensive meta-
analysis looking at the quality of the papers was not performed due to the heterogeneity of the avail-
able published data. 
 
1. The Measure 
SWBN is quantitatively measured using a validated questionnaire, calibrated into a scale known as 
the SWBN scale. The SWBN scale is an internationally established measure used to evaluate the 
overall subjective experiences of patients with psychotic disorders who are on treatment, irrespec-
tive of their psychopathology (19). The scale was initially developed in Germany to assess perceived 
reduction in patient quality of life, focusing on emotion, cognition, and spontaneity (27). It was 
initially a 54-item scale, later reduced to a 38-item scale, and has now been modified to a 20-item 
scale to facilitate easy administration in clinical and research settings. The 20-item Subjective Well-
Being Under Neuroleptic Treatment Scale (SWN-K 20) captures subjective experiences cross five 
dimensions of mental functioning: i) self-control, ii) emotional regulation, iii) physical functioning, 
iv) mental functioning and v) social integration, which is demonstrated through its 5-factor psycho-
metric structure. Each dimension consists of 4 questionnaire items. The scale is a self-report inven-
tory with a Likert-scale comprising six response categories ranging from 1 (not at all) to 6 (very 
much). This shorter version, with the same dimensions, has demonstrated similar psychometric 
properties to the original 38 item scale (28), with high internal consistency for the total scale 
(Cronbach’s alpha=0.97) and subscales ( Cronbach’s alpha between 0.73 and 0.88 ). The SWN-K 
20 has demonstrated good construct validity with other patient-rated scales used to assess the quality 
of life such as the Profile of Mood Scale (POMS), Self-rating Depression Scale (SDS) and Befind-
lichkeits Scale (BFS).  
 
The SWN-K 20 has since been translated into more than 40 languages (29) including Italian (23), 
Korean (25), Greek (26) and Estonian (24), with acceptable psychometric properties. (20, 23-26). 
Evidence suggests that this scale has not been adapted for use in an African setting. Authors of 
European and Asian translations have concluded that intercultural variations in the conceptualiza-
tion of one's perception of well-being are likely to occur among people with schizophrenia across 
different contexts (25). The phrasing of particular SWN-K 20 items has also been shown to influ-
ence response bias. For example, in the Turkish language adaptation of the scale(30), the total score 
of the scale was seen to be more reliable than sub scores when method effects were controlled for. 
Based on these findings, the first step was to translate the SWN-K 20 into isiXhosa and to examine 
the evidence of its psychometric properties. It was also essential to determine and describe the di-
mensions of the Xhosa translated version of the scale to inform its application.  
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2. Predictors of SWBN 
 
As highlighted above, the patient's demographics, the treatment, and the disease (schizophrenia) 
itself are three categories of factors that have been shown to influence subjective well-being (22). 
A review of studies exploring the association between SWBN and these factors suggests the follow-
ing: 
 
a) Patient demographics 
Available studies undertaken in high-income countries have demonstrated a consistent relationship 
between patient demographics such as sex, age, education, income, and employment status and sub-
jective well-being in schizophrenia (24, 26, 31). It is yet to be established whether the same trends 
would be observed in an LMIC context. 
 
b) Treatment factors 
Overall, SWBN is reported to improve with ongoing treatment (31). Schizophrenia patients access-
ing outpatients' services would then be expected to report better SWBN than those who are receiving 
care as inpatients. The type of neuroleptic, the dosage, duration of treatment, and extrapyramidal 
side effects induced by the medication have been highlighted in the literature as factors that may 
influence SWBN. A review of recent research suggests that optimal dosage of a specific neuroleptic 
rather than the actual class it belonged to, positively correlates with SWBN in  HICs population 
(32). Conversely, extrapyramidal side effects and changes to the medication have demonstrated sig-
nificant negative correlations with SWBN in the same population (31). While all neuroleptics have 
a potential of causing extrapyramidal side effects, first-generation neuroleptics are known to have 
more propensity of doing so compared to second generation neuroleptics. The two classes of neu-
roleptics are documented to have equal efficacy towards psychotic (positive) symptoms of schizo-
phrenia while second generation neuroleptics have superior efficacy on negative symptoms(33-38). 
These are observations made on studies involving Caucasian populations in North America and 
European settings; hence, it is unknown if the same treatment-related factors are of relevance in the 
South African setting. In this setting, there are limited neuroleptic options when compared in HICs. 
The options are further reduced in state facilities, where all involuntary admissions are attended to 
in addition to the bulk of the voluntary mental health services. Furthermore, patients in state facili-
ties who need or opt for neuroleptics in a depot formulation are treated  with first-generation neuro-
leptics due to availability and accessibility(39). State facilities in South Africa have access to only 
one-second-generation depot, Risperidone Consta; this is prescribed to relatively few individuals 
who need to be on a depot formulation due to poor adherence and cannot tolerate first-generation 
neuroleptics. 
 
c) Illness factors 
 
HICs cohorts of individuals with schizophrenia have consistently demonstrated that psychotic 
symptoms, as well as depression and anxiety symptoms, influence SWBN(24, 31, 40). This was 
expected as active symptoms at a specific point in time are known to influence an individual’s per-
ceived well-being. What was unexpected were the findings that the chronicity of the illness did not 
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influence perceived well-being. Those who had a single episode reported significant improvements 
in their SWBN compared to those who have had multiple episodes (31). It is clear that specific 
illness factors such types of symptoms, the severity of symptoms, co-occurring conditions have a 
role in the SWBN among schizophrenia patients(31). These results are yet to be replicated in an 
LMIC context. Adjunct treatment or psychosocial interventions could modify illness factors, and it 
is, therefore, essential to investigate their roles in these settings. 
 
Globally, little is known about the specific role of SUD on the SWBN in an individual with schizo-
phrenia. SUD is an illness related factor that warrants exploration in light of the high prevalence of 
use in individuals with schizophrenia and its established complex multifactorial interaction in mod-
ifying the course of this illness. Furthermore, SUD is a confirmed independent predictor of one's 
quality of life. This has translated into treatment guidelines that call for specific integrated care 
approaches for those with schizophrenia and a co-occurring SUD(6). Hence it is crucial to explore 
the role of co-occurring substance use in SWBN among individuals with schizophrenia. 
 
This study aimed to explore the associations between SWBN and i) demographic characteristics, ii) 
treatment and iii) illness-related factors that have already been established in European and North 
America populations with schizophrenia, in a sample of South African Xhosa people with schizo-
phrenia. Understanding these associations in more detail has the potential to provide targets for 
psychosocial interventions aimed at improving adherence and overall treatment outcomes.  
 
HYPOTHESES 
The following hypotheses guided the study: 
1. While patient demographics have not proven to be significant predictors of SWBN in European 
and North American patients with schizophrenia, South Africa still contends with social, eco-
nomic, environmental, and historical legacies. The hypothesis is that as a result, patient de-
mographics may show more significant associations with SWBN in this sample. 
 
2. The associations between subjective well-being and schizophrenia treatment and illness factors 
that have been established in North American and European cohorts can be replicated in the sam-
ple of South African Xhosa people with schizophrenia. 
 
RESEARCH AIM 
This study aimed to: 
A. Translate the 20 items Subjective Well Being under Neuroleptic Treatment scale (SWN-K 20) 
into Xhosa and evaluate its psychometric properties. 
B.  To investigate and identify demographic and clinical predictors of subjective well-being in a 
sample of Xhosa people with schizophrenia on neuroleptic treatment. 
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ABSTRACT 
 
Background:  
Subjective well-being when on neuroleptic treatment (SWBN), has been established as a good pre-
dictor of adherence, early response, and prognosis in patients with schizophrenia(1, 2). The 20-item 
subjective well-being under neuroleptic treatment scale (SWN-K 20) is a self-rating scale that has 
been validated to measure SWBN(3). However, the SWN-K20 has not been previously used in a 
Low- and Middle-income country (LMIC).  
 
Aims and Objectives: 
This study explored the psychometric properties of SWN-K20 in a sample of Xhosa speaking Afri-
can patients with schizophrenia and investigated factors associated with SWBN in this population. 
 
 
Methods: 
As a part of a large genetic study, 244 study participants with a confirmed diagnosis of schizophrenia 
completed the translated SWN-K 20 scale. Internal consistency analysis was performed, and con-
vergent analysis and exploratory analysis were conducted using Principal Component Analysis 
(PCA). . Linear regression methods were used to determine predictors of SWBN in the sample pop-
ulation. 
Results: 
The PCA extracted four components, which cumulatively explained 52.21% of the total variance. 
The internal consistency of the SWN-K 20 was 0.86, and those of the sub-scales ranged between 
0.47 and 0.59. The total scores of the SWN-K 20 demonstrated moderate correlation r= 0.44 with 
GAF scores. The sub-scale scores had lower correlations ranging between r=.41 and r=.30 with the 
GAF scores. The total scores on SWN-K20 scale were used to explore factors influencing SWBN. 
There was a significant correlation between overall subjective well-being score with a higher edu-
cation level, increased illness severity, and GAF scores. 
Discussion and Conclusion: 
The isiXhosa version of the SWN-20 scale can be used for clinical and research purposes in LMICs, 
but predictors of SWBN in this population differed from those previously established in (high-in-
come countries) HICs. The individual sub-scales of the SWN-K20 were less reliable when translated 
 	
into isiXhosa, and hence the sub-scales were not a meaningful measure of specific domains of well-
being. These findings merit evaluation to determine whether cultural and linguistic specific sub-
scales might provide further insight and recommendations for use in the South African context. 
t. 
Keywords: Schizophrenia, subjective well-being, subjective well-being under neuroleptic, SWBN 
 
 
Predictors of SWBN in this LMICs population were not comparable to those in HICs setting(5, 6). 
Older patients with a lower baseline level of education, poor global functioning, and less severe 
symptoms were noted to have lower SWBN and hence at risk of poor compliance. This infor-
mation could guide clinicians, researchers, and interventions that aim at improving compliance 
and the treatment experiences of this patient group. 
 
 
 1 
CHAPTER 2: BACKGROUND 
 
Severe mental illness (SMI) is responsible for 7.4% of the global disease burden(1) and is estimated 
to account for 6% of the disease burden in South Africa(2). Schizophrenia exerts the highest disa-
bility burden compared to other diseases within this category of SMI (4) Schizophrenia is a disorder 
with positive symptoms (disturbance in perception, belief or thinking and disorganized behaviour), 
negative symptomsweakor social interaction, poverty of speech and or anhedonia), mood symptoms 
and cognitive deficits (3). About half of those diagnosed with schizophrenia will also meet criteria 
for a substance use disorder (SUD) (5 ).Dual diagnosis is a term that is useto categorize individuals 
with mental illness and a co-occurring SUD clinicallyUD. This co-occurrence or presence of a dual 
diagnosis compounds the existing disability burden and has treatment implications(6, 7). Efforts 
towards reducing this burden have identified overall improvement in patient’s quality of life and 
functional well-being among the key goals in the treatment of schizophrenia(10). Poor adherence to 
prescribed treatment is one of the hindering factors in attaining functional recovery for people with 
schizophrenia(10). The society incurs an additional burden ithe n form othe f increased burdetoon 
clinical resources in cases of poor treatment outcomes often as a consequence of poor treatment 
adherence(5). 
 
Identification of factors that influence adherence to treatment among individuals with SMI such as 
schizophrenia is an area of global concern(41-43). Several studies have identified, individual’s sub-
jective well-being while on neuroleptic treatment (SBWN), as a good predictor of adherence, early 
response, and prognosis in patients with schizophrenia (17-19). The term "subjective well-bei,"", 
has been defined as an assessment of one's own perception  the   mental, physical and emotional 
state of wellness(20), it is also a construct used to asses an individual’s quality of life (21). Factors 
that influence subjective well-being and consequent,ly the quality of life include those related to the 
i) patient, ii) treatmenoror iii) the disease itself (22). While there is available literature on the SWBN 
among individuals with schizophrenia, less is known about the role of co-occurring SUD on SWBN 
despite thsignificantlynt high prevalence of dual diagnosis. Treatment guidelines for those with 
schizophrenia and a co-occurring SUD call for specific integrated care approaches and have cost 
implications(5-. 
Furthermorere, SUD is a confirmed independent predictor oan f individual’s quality of life. This 
raises the question about the role of SUD in SWBgivenof its complex interaction in SMI and general 
wellbeing(44). There is, therefore, a need to include SUD when exploring predictors of SWBN in 
individuals with schizophrenia. 
 
The absence of data on factors influencing SWBN within LMIs, translates into an absence of cus-
tomized evidence-based interventions targeting poor adherence. This gap needs to be addressed in 
order to decrease the overall disease burden by improving functional recovery with better treatment 
adherence. Moreover, all disease-related factors could potentially be targeted by revising treatment 
approaches, inclusive of psychosocial intervention. It , s thereforeessentialnt to establish evidence 
to inform population-specific interventio.ns   
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Factors that may influence SWBN 
As highlighted abovethe , patient's demographics, the treatme, t and the illness itself are three cate-
gories of factors that have been shown to influence SWBN (22). Below is a review of studies con-
sidering the association between SWBN and these factors: 
 
Patient demographics 
Studies have demonstrated no consistent relationship between patient demographics such as sex, 
age, education, income, and employment status and SWBN within the Caucasian population with a 
diagnosis of schizophrenia (24, 26, 31). It had not been established whether the same trends would 
be observed in an African population from LMICs. 
 
Treatment factors 
Overall subjective well-being is noted to improve with ongoing treatment (31). Treatment-related 
factors that may influence SWBto N include 1)The class of neuroleptic, 2) the dosage, 3) duration 
of treatme, t and 4) side effects experienced by patients on treatmen t.A review of recent research 
suggests that optimal dosage of a specific neuroleptic rather than the class it belonged to, positively 
correlates with SWBN, while treatment side effects and change in medication negatively correlates 
with SWBN (31). All neuroleptics have the potential of causing extrapyramidal side effects, but 
first-generation neuroleptics are known to have more propensity of doing so compared tthe o second 
generation. The two classes of neuroleptics are documented to have equal efficacy towards positive 
sympto, s while the secongeneration neurolepticscs are noted to be superior in addressing negative 
symptoms of schizophrenia(35, 45). The available research, however, has been limited to Caucasian 
populations in North America and European settin;gs hen,ce it was unknown if the same treatment-
related factors are relevant ithe n South African setting. A setting with limited treatment options for 
individuals accessing state facilities and need to be on depot formulation. Available depot neuro-
leptics are from the first generation clasexcept forof Risperidone Consta, which is limited to a few 
individuals wituniqueal motivation(39). Such motivation typically occurs in a specific tertiary or 
specialized facilities by a specialist practitioner. 
 
Illness factors 
Depression, anxie, y and psychotic symptoms have been shown to consistently influence SWBN 
in people with schizophrenia(24, 46, 47). This was expected as active symptominfluencees an in-
dividual's perceived well-being. What was unexpected were the findings that the chronicity of the 
illnesdid not influenceon one's SWBN while those who had a single episode reported significant 
improvements in their SWBN compared to those who have had multiple episodes (31). It is clear 
that specific illness factors such as symptomatology, illness severity, number of episodes and co-
occurring disorders have been shown to play a role in the SWBN among European and North 
America schizophrenia population(31). It was not clear if the same illness-related factors are of 
relevance ithe n African setting. Co-occurring SUD waincluded inin disease-related factors due to 
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its unique contributiotoin functional well-being and its high prevalence among schizophrenia pa-
tients accessing care in South Africa(48, 49). 
 
The Measure 
The SWBN scale is an internationally established measure used to evaluate the overall subjective 
experience among patients with psychotic disorders who are on neuroleptic treatment, irrespective 
of their psychopathology (19). The scale wainitiallyly developed in Germany to assess perceived 
reduction in patient quality of life, focusing on emotion, cognition, and spontaneity (27). It waini-
tiallyly a 54-item scale, later reduced to a 38-item scale, and has now been modified to a 20 item 
scale to facilitate easy administration in both clinical and research settings. The 20-item Subjective 
Well-Being Under Neuroleptic Treatment Scale (SWN-K 20) captures subjective changes acrosfive 
5 dimensions of functioning: self-control, emotional regulation, physical functioning, mental func-
tioning, and social integration, which are demonstrated through its 5-factor psychometric structure. 
Each dimension consists of 4 items. The scale is a self-report inventory using a Likert rating scale 
of 6 response categories ranging from 1 (not at all) to 6 (very much). This shorter version has been 
found to have psychometric properties similar to the original 38 item scale(28). In its original Eng-
lish form, the scale has demonstrated high internal consistency for the total scale (Cronbach's alpha 
= 0.97) and subscales (Cronbach’s alpha between 0.73 and 0.88). The scale has demonstrated good 
construct validity with other patient-rated scales to asses' quality of life such as the Profile of Mood 
Scale (POMS), Self-rating Depression Scale (SDS) and Befindlichkeits Scale (BFS) (50).  
 
The SWN-K 20 has since been translated into more than 40 languages (29) including Italian (23), 
Korean (25), Greek (2, ) and Estonian (24). Studies have demonstrated comparable psychometric 
properties of the translated language versions of the SWN-K 20 similar to the original version (20, 
23-26). Howeverthe , authors concluded that intercultural variations in the conceptualization of 
one's perception of well-being are likely to occur among people with schizophrenia across different 
contexts (25). The phrasing of particular SWN-K 20 items has also been shown to influence re-
sponse bias. For example, in the Turkish language adaptation of the scale(30), the total score of the 
scale was seen to be reliable than sub scores when method effects were controlled for. Available 
translations have also not been able to replicate the same factor structure as the original long or short 
versions of the scales. Therefore, it iessentialnt to determine and describe the dimensions of the 
Xhosa translated version of the scaltoto inform its application in LMICs settings. 
 
From literature and research, this scale had not been used to measure SWBN ian a LMICs African 
setting. It was not known if this scale could be used to asses SWBN in this population. Specific 
factors that play a role in the subjective well-being among individuals with schizophrenia in this 
context were yet to be determined. Adapting this scale for use in South African Xhosa people with 
schizophrenia to determine factors influencing SWBN was a step towards bridging identified gaps. 
The scale was first translated into Xho, a and its psychometric properties were assessed. The trans-
lated scale was then used to determine demographic and clinical predictors of SWBN in a sample 
of Xhosa people with schizophrenia on neuroleptic treatment. Contrary to other studies, the hypoth-
esis wathat thoseat patient demographics have significant associations with SWBN in this sample 
 4	
due to social, economic, environment, l and historical legacies. Patterns of association between 
treatment and illness-related factors and SWBN were expected to be comparable to other similar 
studies. 
 
METHODS	
a) Sample 
The study population was extracted from a larger cohort of Xhosa people recruited from the Ge-
nomics of schizophrenia in South African Xhosa People (SAX) study. The SAX's participants were 
recruited from the Western and Eastern Cape Provinces of South Africa. These are areas with the 
highest density of Xhosa speakers in the country. The minimum sample size requirement for thtwo 
2 specific aims of the study was guided by their respective analytical principles(51). The first aim 
required a minimum of 200 participants while the second aim of the study required a minimum of 
160 participant s.(51-53) The study ended up recruiting all participants who completed the Xhosa 
version of the SWN-K 20 questionnaire in the specified period and met the inclusion criteria. A total 
of 244 participants were recruited in this sub-study. The sample size satisfied both analytical prin-
ciples. 
 
b)	Data	Collection	
Only the identified variables of interest for each participant were extracted, link, d ananalyzeded. 
Participants' scores for the different scales were linked to the main database to facilitate this. A total 
of 9 sociodemographic and clinical variables were extracted and linked to specific study identifica-
tion code assigned to each participant. The SWN-K 20 score, GAF score, age, sex, the highest level 
of education, medication details, illness severity, treatment setting, and substance use status were 
extracted for each participant. Below are the variables, how they were collected and defined in this 
study.  
 
Socio-Demographic characteristics 
Socio-Demographic variables of interest were age, s, x and the highest level of education. These 
variables were grouped as categorical variables for the analysis. Age was categorized into younger 
(20-39 years) and older (40-59years), sex was categorized into male and fema, e and education level 
was categorized into those with primary school education and with high school and above. High 
school education was defined as having passed grade eight and above while those who had less than 
a grade 8 education were classified as having a primary school education. 
 
SWN-K 20 
The SWN-K 20 was used to measure the subjective well-being of the study participants. The SWN-
K 20 was translated into Xhosfollowingth translation guidelines prescribed by the World Health 
Organisation(54). The steps included: 
i) Forward translation of SWN-K items from English into Xhosa by a team of first language 
Xhosa speaking psychiatric nurses; 
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ii) The team then discussed the resultant translated Xhosa version, m and necessary edits or 
amendments were made as per agreement 
iii) Back-translation of the scale into English was performed by an independent first lan-
guage Xhosa speaking psychiatric nurse to deliberate ovethe r conceptual equivalent. 
The translation team included five-first language Xhosa speaking psychiatric nurses, and a psychi-
atric registrar. All clinicians were aged between 24-50 years, bilingual in English, with extensive 
training and experience in conducting clinical interviews and assessments with Xhosa people with 
schizophrenia.  
The SWN-K 20 produces a score that ranges between 20 (lowest) and 120 (highest). This scale was 
used as a continuous variable. The SWN-K 20 also providefive subscalele scores across thfive 5 
specific domains of subjective well-being. However as noted in the literature, it has beechallenginglt 
to replicate the psychometric structure of the tool across different language versions, detracting from 
the validity of thessubscalele scores in translated language versions of the tool ( ). . 
Global functioning 
The global functioning of SAX participants was assessed using the Global Assessment of Function-
ing (GAF) scale. This is a standardized method of assessing the severity of psychiatric illness against 
the overall level of functioning(55). Participant functioning is rated on a scale from 0-100 (56). 
These GAF scores were used as a measure of convergent validity with scores obtained from the 
Xhosa version of SWN-K 20 used ithir s study. 
 
Diagnosis, Illness severity and co-occurring SUD  
The Structured Clinical Interview DSM-IV Axis I Disorders (SCID-I) ( 57), was used during the 
clinical interview with SAX participants to determine whether participants met the DSM-IV diag-
nostic criteria for schizophrenia. Data on illness severity and co-occurring conditions such as SUD 
were also collected as per the DSM-IV classification using the SCID-I. The following four illness 
and treatment-related variables (see table below), extracted from this clinical assessment, were 
grouped and used as categorical variables in our analysis. 
  
Illness antreatment-relateded variables with their assigned categories 
Variable 	 Categories 	
Severity	 1. Full remission to mild symptoms 
2. Moderate to severe symptoms 
Treatment setting	 1. Outpatient 
2. Inpatient 
SUD status	 1. Y, s i.,e. those who met the DSM-IV diagnostic criteria for a SUD. 
2. No, i.,e. those who did not meet the DSM-IV criteria for a SUD.	
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Variable 	 Categories 	
Medication	 1. Second generation neuroleptics 
2. First generation neuroleptics 
 
 
b) Statistical analysis 
Statistical analysis was carried in 2 consecutive steps; 
First step: Principal component analysis (PCA) was used to investigate the psychometric structure 
of the translated SWN-K 20 questionnaire, while internal consistency was established across the 
total scale and subscales using Cronbach alpha. Cronbach alpha above 0.7 was considered as ac-
ceptable. Convergent validity was established using correlations with participant GAF scores using 
Pearson's correlation coefficients.  
 
Second step: Linear regression was used to identify significant predictors of SWBN. The group 
difference was determined using a 95% confidence interval where p-values less than 0.05 were re-
garded as statistically significant. Frequencies (in percentages) and means were used to describe 
numerical data in both step 1 and 2 of the analysis.  
 
RESULTS		
Descriptions of the data  
 
Participants Demographics 
The total sample of 244 Xhosa people with Schizophrenia was recruited between August 2015 and 
January 2017. The sample included 222 males and 22 females. Participants were recruited from 
in/out-patient facilities and required a diagnosis of schizophrenia. The participant age ranged from 
20 to 59 years of a, e with a mean age of 36.45 years. Only one participant reportehavingve no 
formal education. This participant was merged with those with less than primary education during 
the analysis. A majority (66%, n=161) of the participants had obtained some form of secondary 
school education. These demographics are summarised in Table 1.  
 
Treatment factors 
Almost equal numbers of participants were recruited from inpatient (n=129, 52.9%) and outpatient 
facilities (n=115, 47.1%). Second generation neuroleptics were used by 20.9% (n=51) of partici-
pants. 
 
Illness factors  
The majority of the participants (82.8%, n=202) exhibited moderate to severe symptoms, and about 
half of the entire sample study (49.2%, n=120) met the diagnostic criteria for a co-occurring SUD.  
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Table 1: Sociodemographic characteristics and clinical profile of the study population 
 
SOCIODEMOGRAPHIC CHARACTERISTICS (N=244) 
SEX  
Male 222 (90.0%) 
Female 22 (9.0%) 
AGE 
Younger: 20-39 153 (62.7%) 
Older: 40-59 91 (37.3%) 
EDUCATION 
Primary school education 83 (34.0%) 
High school and above 161 (66.0%) 
CLINICAL PROFILE (N=248) 
SEVERITY 
Full Remission to mild symptoms 42 (17.2%) 
Moderate to Severe symptoms 202 (82.8%) 
TREATMENT SETTING 
Outpatient 115 (47.1%) 
Inpatient 129 (52.9%) 
MEDICATION 
Second generation 51 (20.9%) 
First generation  193 (79.1%) 
SUBSTANCE USE 
Yes 120 (49.2%) 
No 124 (50.8%) 
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Psychometric Properties of the SWN-K 20 questionnaire 
Exploratory Factor analysis  
An exploratory factor analysis (EFA) was performed using Principal Component Analysis (PCA) 
and Varimax rotation. The varimax rotation method was select, d as no assumption was made re-
garding any correlation between the factors(58). Emerging patterns were explored, and the findings 
were compared to those of other translations and the original version of the SWBN scale. The Kai-
ser-Meyer-Olkin (KMO) Measure of Sampling Adequacy was 0.879 and a significant Bartlett's Test 
of Sphericity (x2 = 1437.595, p<0.001) suggestenn a adequate sample size for the analysis. Unlike 
the original version that hafive 5 components, analysis of the Xhosa version extractefour 4 compo-
nents with an Eigenvalue of greater than 1 (see Figure 1 below). The first component explained 
28.6% of the total varian, e while thfour 4 components together explained 52.2% of the total vari-
ance. Table 3 summarises the loadings of the questionnaire items across thfour 4 components. Co-
efficients of less than 0.3 were suppressed.   
 
Table 2: Figure 1: Scree plot illustrating the extracted components with their Eigenvalues 
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Table 3: Thfour 4 extracted components and their specific item loading on of the SWN-K 20 
Xhosa version 
 
 
* 
*Items which loaded on more than one component. Only the highest loading is shown in the table and 
grouped accordingly. 
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SWN-K 20 questionnaire items clustered together in different ways in the analysis, compared with 
the original English language version of the tool. Some (7) items, had loadings of greater than 0.3 
in more than one component. These items were placed in the component where they had the highest 
loadi, g i.,e. Item 6 loaded in Component 1,, 2 and 4 with 0.422, 0.3, 7 and 0.3, 1 respectively. The 
remaining 13 items that had only one loading with greater than 0.3. These 13 items were explored 
for possible themes within their respective components. 
 
The first component in the analysis contained 7 SWN-K 20 items. Items that only loaded once, in 
this specific component (those without an Asterix onhe t table) appear to tap into a positive sense 
of control over one's emotional, social and cognitive wellbeing. The items highlighted autonomy, 
agen, y and creativity as one navigates between being an individual entity with several functional 
facets and being part of a larger functional unit such as a family or community. The second compo-
nent was the converse of this. It grouped items that expressea d loss of control and connection within 
the individual and with the external environment. The theme was that of loss of control, autonomy, 
agen, y and connection with both internal and external environment. The third and fourth compo-
nents had the least number of items, focusing on physical functioning and loss of self-contr, l re-
spectively. Further analysis of these components and their emerging themes was beyond the scope 
and aims of this thesis. 
 
Reliability 
The scale (SWN-K 20) as a whole demonstrated high internal reliability with a Cronbach alpha of 
0.863, suggesting that itl items correlated well and tapped into one dominant construct. The indi-
viduasubscaleses showed lower internal reliability, with emotional regulation having the lowest 
value (α=0.468) and physical functioning the highest (α=0.588). This range was at best "poor" ant 
worst "not acceptable" (59), however, Cronbach’s alpha is known to be subjected to inflation or 
deflation by too many or too few items (60).  
 
Validity 
All subscales had a strong correlation with the overall scale (SWN-K 20), suggesting good scale 
validity. When correlated with the GAF score, the overall scale demonstrated the highest conver-
gence validity (r=0.44) while the subscales yielded values ranged from 0.30 to 0.41. These results 
indicate that the SWN-K 20 overall scale score and the GAF score are positively associated, con-
sistent with the expectation that people who experience higher subjective well-being also tend to 
have better overall functioning in their lives. However, correlations between the SWN-K 20 sub-
scale scores and GAF scores were less than 0.4 and closer to 0, 3 suggesting a weak correlation (61, 
62).  
 
These findings when combined with the results of the psychometric structure and internal reliability 
presented above, indicate that the overall score on Xhosa version of the SWN-K 20 to be relativelyly 
reliable and valid indicator of subjective well-being. However, thsubscalele scores are less mean-
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ingful and should be cautiously interpreted. Based on this observation, the second step of the anal-
ysis (determining predictors of SWBN) used the total score on the SWN-K 20 for each participant. 
The subscales scores and the emerging components were not used in any further analysis. The mean 
SWBN score for the sample was 91.85 (SD=14.89). 
 
Table 4: Psychometric properties of the SWN-K 20  
 
Scale and Sub-
scales 
Cronbach’s al-
pha 
Correlation with 
SWN-K 20 
Convergent validity with GAF 
scores 
SWN-K 20  0.86 1.0 0.44 
Mental functioning 0.56 0.82 0.33 
Emotional regula-
tion 
0.47 0.82 0.39 
Physical function-
ing 
0.59 0.77 0.34 
Self-Control 0.50 0.78 0.41 
Social Integration 0.54 0.85 0.30 
 
 
Demographic and clinical predictors of SWBN  
Linear regression method was applied to determine the influence of demographic and clinical factors 
on the SWBN scores. A total of 8 predictors (see table 5) were selected as guided by the literature 
review. A significant regression equation was found (F (8, 235) =10.259 p <.000), with an R² of 
0.259. The model had a significant p-value (p<.000) and accounted for 23.4% of the total variance 
in SWBN scores. The change in SWBN scores that could be attributed to theight 8 variables was 
less thafavorablele (less than 30%). This suggests that theight 8 variables in the model do not influ-
ence one's subjective well-being to a significant extent.  
 
A higher level of education and higher GAF score were significantly associated with increased 
SWBN. Increased symptom severity was also significantly associated with higher reports of SWBN 
in the sample, while participant sex, treatment setting, class of neurolept, c and co-occurring SUD 
did not demonstrate a significant association. Results are summarised in Table 5 below.  
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Table 5: Multiple linear regression table for Predictors of SWBN 
 
Model Unstandardized 
co-efficient Beta	 Std. Error	 P – value CI:95% 
Constant 56.61 10.68 <0.01 35.56-77.66 
GAF Score	 0.39	 0.06	 <0.01	 0.27-0.52 
Age -3.54	 1.81	 0.05	 -7.10-0.03 
Sex -0.25	 3.26	 0.94	 -6.67-6.18 
Education 3.95	 1.85	 0.03	 0.31-7.60 
Severity 7.55	 2.28	 0.01	 3.07-12.05 
Treatment setting -0.43	 1.97	 0.83	 -4.30-3.44 
Medication 0.31	 2.20	 0.89	 -4.02-4.63 
Substance use -1.05	 1.84	 0.57	 -4.67-2.57 
 
 
 
DISCUSSION	
The main findings are those focused othe n psychometrics of the Xhosa version of the SWN-K 20 
and those focused on predictors of SWBN among individuals with schizophrenia ian a LMIC. The 
findings were compared with the available literature and or similar studies addressing SWBN. This 
section will conclude with a reflection of what the findings mean to a patient, clinical practice, 
research activiti, s and identifiea d knowledge gap within the limits of the study design.  
 
SWN-K 20 Xhosa language version  
Data on the psychometric properties of the SWN-K 20 Xhosa language version indicates that this 
tool provides a meaningful overall indication of self-reported experiences of SWBN in the sample 
of Xhosa people with schizophrenia. However, the subscale scores of this measure proved more 
problematic. This finding is consistent with other South African studies exploring linguistic and 
cultural limitations when attempts are made to translate psychiatric scales or clinicainterviews intoto 
African languages, particularly Xhosa (63-65). Campbelet al.al in a study translating Clinical Out-
comes in RoutinEvaluation-Outcomeme Measure (CORE-OM), highlighted challenges in attaining 
equivalent Xhosa translation for items capturing psychological distress. The CORE-OM is a meas-
ure of general distress and dysfunction developed in the UK. Phrases like "I have felt panic or terr,"", 
led to inconclusive debates on the appropriate Xhosa word to depict panic ("Bendinophaphazela,” 
or “Bendinongxungupholo), while differentiating it from terror ("noloyiko"). Sections of the CORE-
OM which explored physical and tangible symptomi.e. ,.e “I have felt unhappy” (“Ndizive ndin-
gonwabanga”), proved easier to translate. The overaloutput wasas a partial measurement scale that 
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omitted items that had no conceptual equivalence in Xhosa language and recommendations for ad-
aptation of specific Xhosa terms to capture psychological distress instead of engaging on translation 
from western constructs (64). 
 
One reason for the difficulty in replicating psychometric structures and validatinsubscaleses across 
different language versions of tools could be the loss of linguistic nuances during the translation 
process(66). Often, translators struggle to find linguistically equivalent terminology in Xhosa for 
English words, particularly emotional construcs, and instead have to use descriptions that convey a 
broader conceptual meaning. Cultural differences in expressing physical, mental, emotion, l and or 
psychological well-being may also play a role in challenges faced during translation of psychometric 
tools from western language to African languages (67, 68).  
 
Explanatory models for mental illness in Sub Saharan Africa (SSA) are highly varied within socie-
ties and even more diverse when compared with Western societies (69). The Xhosa community has 
been identified as one of the SSA communities whose classification of psychiatric symptoms over-
laps more closely with Western explanatory models, and yet there remains a marked reliance on 
traditional cultural explanations of illness(70). In additionbehavioralal and emotional changes in a 
person are often used to identify mental illness in an individual. Cognitive symptoms are often 
missed (and translated according to societal values when recognized), while psychotic features such 
as hallucinations are often given a cultural interpretation ( 65, 69). Particular explanatory models 
are associated with specific illness percepti, n along with help-seekinbehaviorur and treatment sat-
isfaction. A common cultural belief among individuals with schizophrenia in this community is the 
belief that one is experiencing mental illness as a result of being bewitched by a jealouneighborur 
or associate (65, 71, 72 ).This is associated witreducedor engagement with healthcare services and 
prognosis. More importantly, these explanatory models shape how peoplrecognizese and talk about 
their symptoms, and these understandings shape experiences of subjective well-being. 
 
Therefore, while a tool like the Xhosa version of the SWN-K 20 provides some overlap in general 
experiences of SWBN in this sample, it is likely that more culturally and language-specific experi-
ences of well-being are not accounted for in this measure. Similarly, the subscales may be tapping 
into more culturally specific experiences of subjective well-being relevant to Western contexts. 
While the SWN-K 20 Xhosa language version may not fully reflect or share the same measurement 
equivalence as the English language version, the tool does provide some insight into the self-re-
ported experiences of subjective well-being of Xhosa people with schizophrenia on neuroleptic 
treatment in a broad or general sense.  
 
Predictors of SWBN in the Xhosa population 
The analysis identified some predictors of SWBN in Xhosa people with schizophrenia. However, it 
is acknowledged that the identified variables do not occur independently but collectively contribute 
to an individual patient profile. 
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Demographic factors 
Education status was found to be a significant predictor of SWBN in this sample. Age and sex of 
the participants did not demonstrate significant influence on the subjective well-being scores, sim-
ilar to studies conducted in HICs (19, 21, 24). 
 
i) Education: 
International studies suggest higher education to be positively correlated with SWBN(73). The same 
association was observed in this study population. Qualifying for high school or higher tertiary ed-
ucation is often an interaction of higher socioeconomic status, better functional, and goal directness. 
The interpretation of the observed association between education and SWBN is limited by the fact 
that it did not include a variable for socioeconomic status (74). 
 
Clinical predictors 
Global functioning and symptom severity are clinical predictors that demonstratea d significant as-
sociation with SWBN scores of the study participants. The direction of associations varied to those 
observed in HICs. Observed associations between SWBN and co-occurring SUD in the sample was 
similar to earlier studies within HICs.  
 
a) Global functioning 
GAF scores were the most significant predictor of SWBN in the present model. This was expected 
as both SWN-K 20 and GAF scores are instruments used to measure constructs of quality of life. 
Furthermore, a moderate correlation was established between GAF scores and SWN-K 20 scores in 
this specific population in the first part of the study. The findings were similar to other studi,es 
where a correlation between the two scores was moderately correlat, d and global functioning was 
among the clinical factors thawereas independently associated with SWBN(24, 25). 
 
b) Symptom severity 
Moderate to severe illness was associated with higher scores of SWBN. This is contrary tgeneralal 
expectations with worsening of one's psychiatric symptoms. Similar studies in HICs have reported 
mixed findings on the association between symptom severity and SWBN(24, 31). The majority of 
the studies have noted SWBN to be negatively influenced by symptom severity and affective symp-
toms(73).  
 
c) Co-occurring SUD  
The study did not find any association between co-occurring SUD and SWBN. The influence of 
SUD on SWBN remains poorly understood. The review by Vothknecht et al. identified individuals 
studies that found no association between coffee or smoking use disorder and SWBN whila e re-
duction in cannabis cravings was associated with positive SWBN(73). It is evident that the role of 
SUD on SWBN is complex despite the paucity of data. Factors such as specifying the actual sub-
stance of abuse, the number of substances abused, the severity of the use disord, r and characteristics 
of the specific population could bsignificantnt when exploring this relationship. Sucan h in-depth 
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exploration of the multi-faceted roles of substance use or SUD on one’s general wellbeing was 
beyond the scope of this study. 
 
STRENGTHS AND LIMITATIONS 
First, the cross-sectional study design and characteristics othe f sample populatiolimitts the infer-
ence to the broader patient population. The cross-sectional design of the study does not allow tcon-
cludeng the influence of neuroleptics on the SWBN across time. The duration of illness does not 
directly translate to the period that the individual has been consistently on neuroleptic treatment. 
The study recruitenine 9 times more male participants than female. This is possibly a result of the 
recruitment strategy. It is likely that in these faciliti,es men were more often diagnosed with schiz-
ophrenia and women, presenting with more of a mood component, were diagnosed with bipolar 
disorder, excluding them from the study. 
 
Second, data on three clinical factors that may hava e specific influence on one's SWBN was not 
collected. The dose of the neuroleptic, the presence or absence of adjunct medicati, n and dominant 
symptoms exhibited by the participant were not documented. The percentage of D2 receptor occu-
pancy that is associated with the dose and individual pharmacokinetic profile is linked with the 
resolution of symptoms or exhibition of side effects. There is a fine line between attaining the de-
sired effect versus unwanted side effects. This is a critical point and may tip the scale between good 
to poor SWBN. Neuroleptics have been observed to target positive symptoms with less impact  af-
fectiveve and cognitive symptoms. Adjuvant medications have been identified and are clinically 
used to target affective symptoms and improve overall cognition. Negative symptoms are known to 
be associated with lower SW, N while positive symptoms appear to have no to low significant in-
fluence on SWBN(75)irrespective of symptom severity. Thpotentiallyal negative effect on cognition 
as a result of neuroleptics and adjunct medication was not looked at anneededds to be taken into 
consideration. These areas were beyond the scope of this study but are potential areas for further 
resear.ch   
 
Third, two psychological fallacies, affective falla, y and the reality distortion fallacy may have 
skewed findings. The potential of skewed findings due to psychological fallacies should be consid-
ered despite the measures taken to ensure that research participants understood the questionnaire, 
had the capacity for self-expression and evidence that patients with SMcanto respond to SWN-K 
20. Affective fallacy is an error produced whethe emotion elicited by the content influences one's 
judgment, t i.,e. a depressed individual reporting to have more inferiorer quality of living while 
reality distortion fallacy is an error produced when the interpretation of context is influenced by 
individual mental sta, e i.,e. perceptual disturbances may distort one's discernment of their wellbe-
ing. These fallacies are known to distort subjective reports of an individual's patient's quality of life 
and well-being and should be taken into consideration( 76). 
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CLINICAL AND RESEARCH IMPLICATIONS 
i) The SWN-K 20 Xhosa language version holds potential clinical and research utility as 
an overall measure of SWBN in Xhosa people with schizophrenia. However, the sub-
scales did not demonstrate adequate validity or reliability in the current Xhosa language 
version. 
ii) The analysis suggests that those with lower education, poorer global functioning (low 
GAF scores) and less severe symptoms are more likely to have lower SWBN and may 
be at risk of poor compliance. This informatiohelps provideng guidance for clinicians 
and researchers regarding interventions to improve compliance, outcom, s and the treat-
ment experiences in a population that is characteristically similar to this patient group. 
iii) The study focused on a translated measure athe a first step in cultural adaptation. Further 
research might be considereto tailor the items to the specific context and culture cultur-
allyre. The newly generated components merit further evaluation to determine whether 
cultural and linguistic specific subscales might provide further insight and recommenda-
tions for use ithe n South African context.  
 
CONCLUSION 
Patients’ perception of well-being while on neuroleptic treatment is an essential area of focus when 
aiming at improvinpatient-centereded treatment, complian, e and overall treatment outcome. Treat-
ing individuals with SMI ichallenginglt and madmore complicatedex whea n patient's treatment 
experience and expectations are not elicited. Having a self-reported measurement like the SWN-K 
20 available in a validated Xhosa language version provides helpful, possibly broad insights into 
the subjective well-being experiences of this patient group. Future studies should explore specific 
symptoms domains that are associated with a change in subjective wellbeing instead of general 
illness severity.  
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